In other recent news, DarioHealth Corp reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -$0.08, compared to the forecast of -$0.2267. The company also exceeded revenue forecasts, reporting $7.6 million against the anticipated $7.51 million, marking a 110% year-over-year revenue growth. Stifel analysts adjusted DarioHealth's stock target to $2.00 from $3.50, maintaining a Buy rating despite the price target reduction. They noted the company's modest sequential revenue growth and the impact of transitions in Twill's customer base, which DarioHealth acquired in 2024. Additionally, DarioHealth is negotiating two substantial contracts, including a behavioral health deal with a national health plan, expected to contribute to revenue in the second half of 2025. The company aims for operational cash flow breakeven by the end of 2025, supported by a projected operating expense reduction of over 20%.